About the Acute Myeloid Leukemia Session
Acute Myeloid Leukemia (AML) is a rapid-progressing hematologic malignancy characterized by the uncontrolled proliferation of immature myeloid cells. Current cancer research focuses on understanding the genetic and molecular basis of AML to develop targeted therapies. Advances in genomics have identified mutations in genes such as FLT3, NPM1, and DNMT3A, providing insights into disease pathogenesis and potential therapeutic targets. Novel treatments, including FLT3 inhibitors and immune-based therapies like monoclonal antibodies and CAR-T cells, are under investigation. Additionally, researchers are exploring the role of the bone marrow microenvironment in AML progression and resistance to therapy, aiming to improve patient outcomes through personalized medicine.
Topics Covered in Acute Myeloid Leukemia
Molecular Risk Stratification
Mutation-Targeted Therapy
Intensive Induction
Low-Intensity Therapy
Stem Cell Transplant
Measurable Residual Disease
Related Scientific Sessions at CIOC 2027
Why Attend the Acute Myeloid Leukemia Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Acute Myeloid Leukemia work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Acute Myeloid Leukemia research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Acute Myeloid Leukemia track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Acute Myeloid Leukemia Conference 2027 — FAQs
What is the Acute Myeloid Leukemia track at CIOC 2027?
The Acute Myeloid Leukemia track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Acute Myeloid Leukemia. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Acute Myeloid Leukemia sessions?
Cancer researchers and clinicians, educators and students with an interest in Acute Myeloid Leukemia are all welcome — whether presenting or attending.
Can I present my research in the Acute Myeloid Leukemia track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Acute Myeloid Leukemia sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Acute Myeloid Leukemia track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.